REG - Verici Dx PLC - Collaboration with Illumina

Verici DxAnnouncement

05/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4292Xa&default-theme=true

RNS Number : 4292X  Verici Dx PLC  05 January 2022

Verici Dx plc

("Verici Dx" or the "Company")

 

Verici Dx and Illumina demonstrate the clinical utility of Illumina's newly
launched data platforms for analytics

 

Readiness for launch, accelerated by Illumina Connected Analytics (ICA),
represents an important milestone in the path to commercialization of Verici
Dx's lead products

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces a pioneering collaboration with Illumina, Inc.
(NASDAQ: ILMN), to expedite the operational launch of data analysis processing
and predictive artificial intelligence component of Verici Dx's products using
early access to ICA, Illumina's new software platform for operationalized
secondary analysis with an advanced data science environment.

 

Verici Dx's underlying technology is based upon artificial intelligence
assisted transcriptomic analysis of proprietary RNA signatures focused upon
the immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, resulting in rejection and graft
failure beginning pre-transplant and following to late-stage.

 

ICA will provide Verici Dx with the ability to process large datasets,
allowing for AI-enabled RNA signature testing to be clinically available at a
more robust level than has been previously possible. ICA also enables Verici
Dx to build custom workflows in a secure and compliant environment. With
streamlined querying of large data sets, ICA supports Verici Dx's leading-edge
technology and provides a framework for future data science discovery. ICA
allows the integration of Illumina sequencers and software in a cloud-based
environment and is accessible globally enabling further expansion and
collaboration opportunities for Verici Dx.

 

Having access to this state-of-the-art platform provides a substantial
enhancement to Verici Dx's data management and interrogation capabilities and
bolsters its ability to develop highly predictive future products. It will
also enable Verici Dx to stay at the forefront of improving patient outcomes.

 

Susan Tousi, Chief Commercial Officer of Illumina, said: "We are pleased to
collaborate with Verici Dx to provide a platform for them to advance their
sequencing analytical methodologies for organ transplant tests. Looking
towards the future of Illumina's software portfolio, Illumina Connected
Analytics is the foundation upon which we are building to get data-driven
answers."

 

Sara Barrington, CEO of Verici Dx, said: "We are delighted to announce the
successful operational launch of the Verici Dx data analysis processing and
predictive artificial intelligence components of our clinical products as
inaugural users of Illumina's new ICA platform. Our leading-edge science
depends on the ability to process vast amounts of data into meaningful and
interpretable segments, and we believe there is no better tool to support us
in this than ICA. We are very proud to be an early-access user of this tool in
the commercial space from a world-class provider and leader in servicing the
global sequencing market.

 

"This milestone represents a key step in the readiness of both the near-term
launches of our flagship Clarava™ and Tuteva™ products, as well as the
long-term strategy for building the computational data analytics tools that
will power the future of Verici Dx's data science. We look forward to
updating the market with our further progress towards commercialization in due
course."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Kailey Aliyar / Tom Salvesen

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalized patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The company also has a mission to accelerate the pace of
innovation by research using the fully characterized data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIMPTMTBMBTT